Precision oncology, genetic testing for diagnosis, prognosis and most effective cancer treatment

Cancer Genes
Test Kit

Cancer diagnosis, prognosis and monitoring by gene testing

Our Mission

Cancer is a highly complex disease caused by a set of oncogenic protein-coding genes and non-coding genes, and, thus, targeted analyses of these genes through highly innovative technologies are the best methods for cancer diagnosis, prognosis, risk assessment and treatment follow-up of various cancers. These are the most powerful research technologies that can save the lives of millions of cancer patients.

Who is GeneVerify Inc.

At GeneVerify, Inc., we have assembled a highly talented, multi-disciplinary team of molecular biologists, cell biologists, pathologists, biochemists, urologists, surgical oncologists, medical oncologists, radiation oncologists, physicians and surgeons committed every day to meeting the challenges of evolving gene-based diagnosis and treatment of various solid tumors.

What is Genetic Profiling​

GeneVerify, Inc., is developing in vitro diagnostic (IVD) reagents for laboratory- based assays for analysis of a set of oncogenic genes in various cancers using real-time PCR technology. We are also developing novel technologies to target these genes that will provide the most effective and highly specific treatment for various cancers.

Our Products

Genes-based Analyses

(Protein coding genes and Non-coding genes analyses) 

Analyses of a set of oncogenic protein coding genes and non-coding genes for in vitro diagnostic assays in research laboratory only. Analyses must be corelated by surgical oncologists/ medical oncologists/ radiation oncologists / pathologists/ physicians/ surgeons/ for diagnosis, prognosis, risk assessment and monitoring therapies of various cancers

Products

In Vitro Diagnostic Reagents (Research and Development)  

Genes-based Therapy

Targeting Oncogenic Protein coding genes and non-coding genes for treatment.  Pre- IND (Investigational New Drug)

Genes based therapies that target oncogenes that are involved in cancer initiation, progression and metastasis.

Products

Research and Development

Pre-IND (Investigational New Drug  

Phase-1         Phase-2        Phase-3

Message from the CEO

“Precision Medicine” is a relatively new approach for disease treatment that takes into account, among other things, individual variability of genes.  The precision medicine approach is based on genetic profiling of a set of tumors. Based on published literature, one in five patients that are newly diagnosed with cancer has a different combination of genetic changes and gene profiling, and, thus, one drug does not fit all with less consideration of the genetic differences between individuals. Therefore, each patient’s tumor has unique, individualized, genetic abnormalities, such as mutation, re-arrangement, translocation, polymorphic variants, gene fusions, gene amplification, gene deletion, abnormalities in microRNAs (miRNAs) and long-non-coding RNAs (lncRNAs), and DNA methylation.

In precision medicine, we must utilize the latest technologies for tumor genomics through multi-omics, such as genome, proteome, transcriptome, epigenome, metabolome, and microbiome profiling. Based on the Human Genome Project data analyses, there are more than 30,000 protein-coding genes and 60,000 non-coding genes.

Our professionals have dedicated their careers addressing cancer genetics and epigenetics for over 40 years and published more than 550 peer-reviewed research papers in high impact journals.

According to the NIH RePORTER database, our laboratory has been awarded / funded research projects 99 times through the NCI/NIH and U.S. Department of Veterans Affairs. We have several US patents in the field of urology and oncology resulting from major NCI/NIH funding initiatives.

At GeneVerify, Inc., we are developing in vitro diagnostic reagents for research laboratory- based assays for analysis of a set of oncogenes in various cancers using real-time PCR technology. We are also developing novel medical technologies to target these oncogenes that will provide the most effective and highly specific treatment for various cancers. These are the most powerful research and innovative technologies that can save the lives of millions of cancer patients. 

Rajvir Dahiya, M.S., Ph.D., M.D., D.Sc.

Founder, CEO and President

Rationale and Approach

According to the Cancer Statistics of 2024, approximately 20 million people worldwide are newly diagnosed with cancer each year. By 2030, this number is projected to double if not properly controlled. A significant issue is the lack of testing for early diagnosis, prognosis, and treatment follow-up. In some Southeast Asian countries, such as India, around 40% of cancer patients are diagnosed at a metastatic stage due to inadequate testing. Nearly all cancer-related deaths are caused by metastasis, and currently, there is no effective therapy for metastatic cancer.

At GeneVerify, Inc., our professionals believe that early identification and intervention, specifically targeting a set of oncogenes, can inhibit cancer progression and metastasis. These cutting-edge technologies will improve patient outcomes while simultaneously reducing healthcare costs.

We have developed a novel blood-based mRNA genomic technology, which holds 5 U.S. patents and has been featured in over 200 original research publications in high-impact journals.

Our blood-based mRNA genomic technology can be utilized for screening, early diagnosis, prognosis, treatment follow-up, and gene therapy for various cancers. These tests have undergone 9 clinical trials across 9 hospitals in the USA, Japan, and India, demonstrating 95% specificity and sensitivity.

Our team consists of more than 50 medical scientists with expertise in medical oncology, surgical oncology, pathology, radiation oncology, molecular biology, genetics, gene therapy, cancer biology, and biochemistry, who have been working in the USA for the past 20 to 40 years.

On January 25-27th, 2024, we presented our data at the ASCO GU symposium (American Society of Clinical Oncology) meeting at San Francisco, California, USA. ASCO has 45,000 members worldwide. This paper was published in the Journal of Clinical Oncology January 29th 2024.

https://ascopubs.org/doi/10.1200/JCO.2024.42.4_suppl.271

On April 5-10, 2024, we presented our data at the AACR meeting (American Association of Cancer Research) at San Diego, CA. AACR has 58,000 members from 141 countries (google search). This paper was published in the Journal “CANCER RESEARCH” March 22, 2024.

https://aacrjournals.org/cancerres/article/84/6_Supplement/2442/741209/Abstract-2442-Blood-based-novel-mRNA-genomic-test

On May 3-6, 2024 we presented our data at AUA (American Urology Association) at San Antonio, Texas. AUA has more than 25,000 members from 138 counties (google search). This paper was published in the Journal “Journal of Urology” May, 2024.

https://www.auajournals.org/doi/10.1097/01.JU.0001008896.93851.5b.05  

It has following advantages:

  1. Screening and early diagnosis when pathological and clinical findings fail to detect cancer. Based on the recent publications 25% of patients that are normal pathologically and clinically, in fact they have cancer based on genetic testing. Most patients die of cancer due to metastasis and if detected early 90% cancer patients can be cured or prolong their lives.
  2. Avoidance of surgery, if the tumor is slow growing, then it can be on active surveillance. Based on published data, 50% of surgeries may not be required since it is misdiagnosed.  
  3. Prognosis of cancer based on genetic profile. If a tumor is aggressive then more aggressive treatments are needed. If the tumor is slow growing then less aggressive intervention is required. Most patients die due to aggressive treatments that may not be required if the tumor is slow growing.
  4. Monitoring of treatment whether the treatments are effective or not. Genetic testing will closely monitor effectiveness of expensive therapies. This will save lives of many patients by undue treatments and save millions of dollars since these therapies may not be working.
  5. To start phase 1 clinical trial of gene therapy using antisense technology. We have a US patent on this technology. Our approach is gene-based diagnosis through genetic profiling and gene-based therapy through inhibition of cancer genes by antisense technology.

GeneVerify’s targeted genetic testing kits are the path to value-based rapid testing, discovery and identification, and risk prediction that is invaluable to early intervention.

Backed by our genetic testing profiling, medical oncologists and surgical oncologists may enable to (i) diagnose early stage cancer (ii) predict whether tumor is aggressive or slow growing and thus provide better decisions for surgery or active surveillance (iii) predict prognosis and risk assessment of cancer based on genetic profiling (iv) better predict how a patient might respond to certain modalities and therapies more accurately, and (v) achieve a solid basis for better decision-making on a patient’s therapeutic treatment and future evaluation to yield the quickest results, thereby enhancing your patient’s health, lengthen life, and reduce illness and disability.

 At GeneVerify, Inc., we are tackling the issues that matter most to patient care in a collaborative setting where teamwork and innovation leads to more answers.

Employees and Advisers

Dr. Rajvir Dahiya is a Retired Professor Emeritus of Urology at the University of California San Francisco, School of Medicine (UCSF). He has 40 years of expertise in medical oncology, cancer genetics and epigenetics research

Rajvir Dahiya, M.S., Ph.D., M.D., D.Sc.

Founder, CEO and President

Dr. Deng is a retired Medical Oncology researcher from the University of California San Francisco School of Medicine (UCSF). He has 45 years of expertise in medical oncology, cancer genetics and epigenetics research.

Guoren Deng, M.D.

Chief Scientific Officer

Dr. M. Allen Northrup is an elected Member, National Academy of Engineering , Bioengineering Section and American Institute of Medical and Biological Engineers. He is a co-founder of Cepheid Inc. He has more than 30 years of expertise in the field of PCR technology and testing.

M. Allen Northrup, Ph.D.

Scientific Adviser

Dr. Dharam P. Chauhan is a retired Professor of Gastroenterology and Hepatology Oncology from University of California San Diego (UCSD) School of Medicine. He has 34 years of expertise in medical oncology, genetics and epigenetics research.

Dharam Paul Chauhan M.S., Ph.D.

Vice-President

Scientific Research Collaborators and Distributors

In vitro Diagnostic Collaborators

Mount Sinai Tisch Cancer Center, New York, NY, USA

Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India

PGIMS and University of Health Sciences, Rohtak, Haryana, India

Inqaba Biotechnical Industries (Pty) Ltd, Pretoria, Gauteng, South Africa

Bioinnotech, Filopappou 34, 11741, Athens, Greece

Global Institute of Stem Cell Therapy and Research, San Diego, California, USA

Scientific Research Collaborators

Osaka University, Graduate School of Medicine, and Faculty of Medicine. Osaka, JAPAN

Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, JAPAN

University of Florida, College of Medicine- Jacksonville, Florida, USA

Case Western Reserve University, School of Medicine, Cleveland, Ohio, USA

Yamaguchi University, Faculty of Medicine and Health Sciences, Yamaguchi, JAPAN

HealthCare Global Enterprises, HCG Cancer Hospital, Bengaluru, INDIA

Max Healthcare Institute Limited New Delhi, INDIA

Oregon Health Science University Cancer Institute Portland, Oregon, USA

Distributor for Netherlands

Sobek Bio

c/o DivBio; P.O. Box 92
4850 AB Ulvenhout
The Netherlands

Publications

A lncRNA TCL6-miR-155 Interaction Regulates the Src-Akt-EMT Network to Mediate Kidney Cancer Progression and Metastasis

Kulkarni P, Dasgupta P, Hashimoto Y, Shiina M, Shahryari V, Tabatabai ZL, Yamamura S, Tanaka Y, Saini S, Dahiya R, Majid

Cancer Res. 2021 Mar 15;81(6):1500-1512. doi: 10.1158/0008-5472.CAN-20-0832. Epub 2021 Jan 26.PMID: 33500248.

LncRNA CDKN2B-AS1/miR-141/cyclin D network regulates tumor progression and metastasis of renal cell carcinoma

Dasgupta P, Kulkarni P, Majid S, Hashimoto Y, Shiina M, Shahryari V, Bhat NS, Tabatabai L, Yamamura S, Saini S, Tanaka Y, Dahiya R.

Cell Death Dis. 2020 Aug 19;11(8):660. doi: 10.1038/s41419-020-02877-0.PMID: 32814766 Free PMC article.

MicroRNA determinants of neuroendocrine differentiation in metastatic castration-resistant prostate cancer

Bhagirath D, Liston M, Patel N, Akoto T, Lui B, Yang TL, To DM, Majid S, Dahiya R, Tabatabai ZL, Saini S.

Oncogene. 2020 Dec;39(49):7209-7223. doi: 10.1038/s41388-020-01493-8. Epub 2020 Oct 9.PMID: 33037409 Free PMC article.

Product order form​

Get in Touch

This website uses cookies to ensure you get the best experience on our website.